

1 **Title**

2 *EFFECTS OF THE ADDITION OF TRANSCUTANEOUS ELECTRICAL STIMULATION TO*
3 *NON-PHARMACOLOGICAL MEASURES IN LABOUR PAIN: STUDY PROTOCOL FOR A*
4 *RANDOMIZED CONTROLLED TRIAL*

5

6 **Abstract**

7 **Background:** Labor, although natural and physiological, is a period that can be marked by stress,
8 pain, anxiety, suffering, fear, anguish for a woman. Thus, non-pharmacological measures to
9 reduce pain during labor are important to allow a better experience without the use of drugs. A
10 non-pharmacological method that has been investigated is the use of Transcutaneous Electrical
11 Stimulation (TENS). Thus, the aim of this study is to assess the effects of non-pharmacological
12 pain relief measures added or not the application of TENS on pain, satisfaction with the childbirth
13 of labor duration and conditions of birth of newborns. **Methods:** This is a randomized controlled
14 clinical trial, with a non-probabilistic sample for convenience, composed of women during the first
15 active phase of labor, admitted to a public institution. The volunteers will be divided into 3 groups:
16 Group 1 (n = 36) composed of parturients who will have continuous support and will be
17 encouraged as to walking, adopting a variety of positions with the use of the Swiss ball and
18 receiving massage in the lower back for 30 min; Group 2 (n = 36) composed of parturients who
19 will also have continuous support and will be encouraged as to ambulation, adoption of a variety
20 of position using the Swiss ball and will receive the application of TENS for 30 min and Group 3
21 (n = 36) composed by parturients who will have continuous support and will be encouraged as to
22 walking, adopting a variety of position with the use of the Swiss ball and will receive application
23 of TENS placebo for 30 min. The outcomes assessed in the study will be: pain intensity assessed
24 by the Visual Analogue Scale of pain applied before, immediately after, 30 minutes and 1 hour
25 after interventions; Delivery Experience and Satisfaction Questionnaire (QESP) applied 12 to 24
26 hours after delivery, data regarding delivery (type of delivery, total duration of labor and possible
27 obstetric complications) and neonate (weight, height, possible complications, score Apgar in the
28 first and fifth minutes). **Discussion:** With this research, it is expected to understand the effects of

29 the intervention through TENS electrostimulation, added to other non-pharmacological pain relief
30 measures, in women in labor.

31 **Trial registration:** Brazilian Registry of Clinical Trials (REBEC), number RBR-68kh6j approved
32 on March 17, 2020.

33 **Keywords**

34 Pain, labor, non-pharmacological pain relief measures, electrostimulation.

35

36 **Introduction**

37 **Background and rationale {6a}**

38 Labor, although natural and physiological, is a period that can be marked by stress, pain,
39 anxiety, suffering, fear, anguish for women [1]. Thus, the World Health Organization (WHO)
40 recommends the use of non-pharmacological pain relief measures such as ambulation,
41 kinesiotherapy or maternal mobility, exercise on a Swiss ball, massage, breathing exercises,
42 relaxation techniques, hot bath with the aim of reducing pain, promoting an active posture of the
43 parturient, with greater autonomy for women [2].

44 Non-pharmacological methods of pain relief can be used alone or together by the
45 multidisciplinary team that make up the hospital structure (physiotherapists, nurses, nursing
46 technicians, doctors and doulas), depending on the parturient's choice and the hospital
47 infrastructure [3, 4, 5, 6]. Some studies have demonstrated the effectiveness of walking and
48 massage therapy in reducing pain and increasing pain tolerance [7,8,9]. Besides that, studies
49 with other methods such as breathing and relaxation techniques, maternal mobility, Swiss ball
50 exercises, massage and hot bath have observed a decrease in the use of medications, a
51 decrease in anxiety and stress, a decrease in the duration of the active phase of labor and greater
52 body perception of the parturient [10, 11, 12].

53 A non-pharmacological method that has been investigated is the use of Transcutaneous
54 Electrical Stimulation (TENS). This is an apparatus by means of electrical stimulation has a pain
55 reduction action and can be used during labor [13, 14]. There are two theories that explain the
56 action of TENS in reducing pain. The first is the theory that was proposed by Melzack and Wall
57 in 1965 that explains the action of TENS through the theory of the pain gate. Thus TENS provides
58 electrical stimulation through the through the skin, sensory stimuli which will be taken to
59 information to the brain via afferent fibers to the dorsal horn of the A β marrow [15, 16]. Thus there
60 is a blockage of pain impulses to the brain such as fiber transmits the information faster than the
61 fibers responsible for transmission of pain [15, 16]. Another theory is explained by the release of
62 endogenous opioids by the brain, as is the case of the release of beta-endorphins, which have
63 an analgesic effect [15, 16].

64 The use of TENS during labor has its placement of electrodes at the levels of the
65 vertebrae T10-L1 and S2-S4 [14, 17]. The sensation that the patient will report is tingling or
66 tickling, and cannot cause muscle contraction or pain during the process. Studies have
67 demonstrated the safety of the method for mother and fetus and positive effects in decreasing
68 pain during work, decreasing the use of complementary analgesia, decreasing anxiety,
69 decreasing labor time and improving satisfaction [13, 14, 15, 16, 17, 18, 19].

70 Despite the number of studies on the use of TENS in labor and its wide use in clinical
71 practice, systematic reviews on the subject make it clear the low quality of studies so far [18, 20].
72 Thuvakaran et al [20], in a meta-analysis, found only a small effect of pain reduction during
73 childbirth with the use of TENS, it is not possible to say whether the results were affected by the
74 low quality of the studies.

75 Furthermore, the reality of clinical practice is the use of the methods of non-
76 pharmacological pain relief together in an attempt to promote greater relief to women. However,
77 the current scientific evidence comes mostly from studies that have evaluated the isolated effects
78 of the techniques [12]. Thus, it is important to analyze the possible additional effect of using TENS
79 in addition to other non-pharmacological pain relief techniques through a clinical trial with greater
80 methodological control. These results may contribute to the physiotherapist's clinical practice in
81 obstetrics, justifying or not the investment in equipment in maternity hospitals.

82

83 **Objectives {7}**

84 The aim of this randomized clinical trial is to verify the effects of non-pharmacological
85 pain relief measures added or not to the application of TENS on pain, satisfaction with delivery,
86 duration of labor and birth conditions of newborns.

87

88 **Trial design {8}**

89 This is a single-blind randomized controlled trial to compare three randomized groups in
90 parallel (1:1:1). This article has been written in accordance with the SPIRIT (Standard Protocol
91 Items: Recommendations for Interventional Trials) guidelines.

92

93 **Methods: Participants, interventions and outcomes**

94 **Study setting {9}**

95 The trial will be carried out in the facilities of the Hospital Municipal Modesto de Carvalho,
96 in the city Itumbiara-GO, Brazil.

97

98 Eligibility criteria {10}

99 Participants presenting the following features will be included in the trial:

- 100 - Pregnant women in active labor;
- 101 - Low-risk pregnancies;
- 102 - Women with a gestational age of 37-42 weeks;
- 103 - Gestation with a single fetus and this one in the cephalic position.

104 Exclusion criteria

105 Patients presenting the following features will be excluded from the trial:

- 106 - having a wound or inflammation in the cutaneous areas of application of the TENS
107 electrodes;
- 108 - presence of a pacemaker;
- 109 - inability to understand verbal commands.

110 Who will take informed consent? {26a}

111 The signed informed consent form will be obtained from each patient prior
112 to their participation in the study. The evaluator will acquire consent during
113 hospitalization. The evaluator will explain all stages of the study and the
114 volunteers who agree to participate will sign the term.

115

**116 Additional consent provisions for the collection and use of participant data
117 and biological specimens {26b}**

118 Not applicable. There will be no biological sample collection in this study.

119

120 Interventions**121 Explanation for the choice of comparators {6b}**

122 In clinical practice, non-pharmacological pain relief resources are used together, in an
123 attempt to promote better results. However, they were not found in literature studies verified by

124 comparing the non-pharmacological measures of pain relief isolated and already recommended
125 by WHO and combined application of TENS, if such action would an enhancement in diminishing
126 pain of pregnant women during labor. Therefore, it was decided to compare non-pharmacological
127 pain relief measures, with the same measures added to the use of TENS and placebo.

128

129 **Intervention description {11a}**

130 The intervention of the three groups will occur during the first active phase of labor, from
131 admission, which happens when the parturient has 4 cm of cervical dilation, until the beginning
132 of the expulsive period. The three groups will receive continuous support from professionals,
133 encouraging walking and the adoption of vertical postures. In addition, parturients in Group 1 will
134 be positioned on a Swiss ball so that they receive massage in the dorsal region for 30 min. Classic
135 massage movements will be used, such as: superficial sliding, deep sliding, kneading, friction and
136 rolling. Farmax brand almond oil will be used as a way to facilitate manual maneuvers.

137 Group 2 women will be submitted to intervention using TENS electrostimulation using the
138 portable Neurodyn Ibramed portable TENS equipment. They will be positioned seated on the
139 Swiss ball and four silicone electrodes that will be fixed with masking tape in the thoraco-lumbar
140 region, at the levels of T10-L1 and S2-S4. A frequency of 100 Hz, pulse width of 100µs will be
141 used, with intensity depending on the sensitivity of each patient for 30 minutes [17].

142 Women in Group 3 will undergo placebo intervention. They will be positioned and will have
143 electrodes fixed in a similar way to group 2. However, the equipment will remain with the intensity
144 button deactivated, without current flow.

145

146 **Figure 1- Image of electrode placement in the thoraco-lumbar region**

147 **Figure 2- Image of the portable TENS Neurodyn Ibramed**

148

149 **Criteria for discontinuing or modifying allocated interventions {11b}**

150 The criterion for discontinuation is withdrawal of patient consent prior to
151 publication of the results.

152

153 **Strategies to improve adherence to interventions {11c}**

154 As this is an intervention that happens only during labor, the researchers
155 will explain in detail the procedure for participating in the project and the need for

156 data collection after delivery.

157

158 **Relevant concomitant care permitted or prohibited during the trial {11d}**

159 During the protocol are allowed oral and intravenous medications as
160 indicated by the doctor, with the exception of analgesic medication. Maternal
161 mobility, bathing, total freedom for the mother in labour are allowed as
162 recommended by the World Health Organization for women in labour.

163 **Provisions for posttrial care {30}**

164 Researchers are responsible for any harm that occurs as a result of the
165 study. Thus, the researchers will provide for participants' health care needs that
166 arise as a direct consequence of trial participation.

167

168 **Outcomes {12}**

169 Primary outcome measure

170 Primary outcome measure is assess the intensity of pain using the Visual
171 Analogue Scale (VAS). It is a simple one-dimensional instrument, used worldwide
172 to assess pain intensity. It is characterized by a 10 cm long horizontal line where
173 0 represents no pain and 10 the worst imaginable or severe pain. They will be
174 evaluated before the intervention, immediately after the intervention, 30 minutes
175 after and 1 hour after the intervention, will also be evaluated in the immediate
176 puerperium (12-24 hours after delivery). All measurements will be performed in
177 the period between uterine contractions.

178

179 Secondary outcome measures

180 The secondary outcomes of the study are evaluate satisfaction with childbirth, using the
181 Childbirth Experience and Satisfaction Questionnaire (QESP). This consists of a self-report

182 questionnaire, with a total of 104 questions, which refer to the expectations, experience,
183 satisfaction and quality of the woman's experience related to labor, delivery and immediate
184 postpartum. This consists of a self-report questionnaire, with a total of 104 questions, which refer
185 to the expectations, experience, satisfaction and quality of the woman's experience related to
186 labor, delivery and immediate postpartum. It is composed of relative Lickert questions divided into
187 eight subscales that comprise it: (1) conditions and care provided, (2) positive experience, (3)
188 negative experience, (4) relaxation, (5) support, (6) support partner, (7) concerns and (8)
189 postpartum. The higher the score obtained in each of the subscales, the more positive the
190 perception of women in the dimension assessed by the subscale. The administration time for this
191 questionnaire is approximately 30 minutes [21]. The questionnaire will be applied in the immediate
192 postpartum period (12-24 hours) after delivery.

193 After delivery, information on the type of delivery, total delivery duration and possible
194 obstetric complications will be collected from the participants' medical records. Besides that, data
195 will be collected on the newborn: weight, height, possible complications, Apgar score in the first
196 and fifth minutes.

197

198 **Participant timeline {13}**

199 Initially, volunteers will be numbered to avoid the risk of being identified.
200 Soon after admission to the hospital, they will answer the standard anamnesis
201 composed of questions about gynecological, obstetric and health history, lasting
202 approximately 10 minutes.

203 Before the start of the intervention, the volunteer will be asked to mark on
204 the VAS line the intensity of her pain at the moment. Immediately after, 30
205 minutes, 1 hour after the interventions with the use of massage, TENS or placebo,
206 the request for indication of pain intensity will be repeated.

207 After 12 to 24h of the completion of the delivery, the volunteer will be
208 visited by the researcher in the rooming-in and will be applied again to VAS and
209 also the Questionnaire of Experience and Satisfaction with Delivery (QESP).

210 Data regarding childbirth, including: type of delivery, total duration of labor
211 and possible obstetric complications, will also be collected by consulting medical
212 records. As for the neonate, weight, height, possible complications, Apgar score
213 in the first and fifth minutes will be collected.

214 The schematic diagram of the participant timeline can be seen in Figure 3.
215

216 **Sample size {14}**

217 Based on a previous study Báez-Suárez et al [14], considering a difference
218 between groups of 1.5 and the standard deviation of 1.61, considering an alpha
219 of 0.05 and the test power of 0.80 , the minimum sample size in each group is 36
220 participants.

221

222

223 **Figure 3:** Flow diagram of the trial design

224

225 **Recruitment {15}**

226 Participants will be recruited from Modesto de Carvalho Municipal Hospital, in the city
227 Itumbiara-GO, Brazil. This hospital has an average of 67 births per month, with a vaginal birth
228 rate of around 43.51%. No advertising is permitted for recruitment and no inducements will be
229 given for the recruitment of patients in the study.

230

231 **Assignment of interventions: allocation**

232 **Sequence generation {16a}**

233 Participants will be randomized in a 1:1:1 ratio to the three groups, group 1 (active posture
234 and massage in lumbar region for 30 minutes), group 2 (active posture and TENS application in

235 lumbar region) and group 3 (active posture and TENS placebo application in lumbar region for 30
236 minutes), by computer-generated random numbers.

237

238 **Concealment mechanism {16b}**

239 A researcher not involved in the data collection will assign the groups by
240 the sealed envelope method. The opaque envelopes will be numbered and kept
241 locked away, available only to the study researchers.

242

243 **Implementation {16c}**

244 After including the participant, the researcher responsible for the
245 interventions will open the envelope with the lowest number available to
246 determine which group the participant belongs to.

247

248 **Assignment of interventions: Blinding**

249 **Who will be blinded? {17a}**

250 The researcher in charge of the interventions to be applied to the
251 participants will be blind to the assessments. The researcher in charge of the
252 evaluations and the one accounting for data processing will be blind for treatment
253 allocation. Patients will not be totally blind to the procedure because of the
254 difficulties set by differences between techniques, but participants in the placebo
255 group will not have information about the operation of the equipment.

256

257 **Procedure for unblinding if needed {17b}**

258 The loss of blinding should not be carried out unless there is a threat to

259 the participant's safety as a consequence of the study procedures.

260

261 **Data collection and management**

262 **Plans for assessment and collection of outcomes {18a}**

263 A trained researcher will perform all assessments during labor and after
264 delivery. VAS is a simple one-dimensional instrument, used worldwide to assess
265 pain intensity. Studies demonstrate that the Visual Analogue Scale is valid,
266 reliable and suitable for measuring pain in the clinical part as in the evaluation of
267 obstetric pain, as well as being reliable for measuring acute pain [22, 23, 24].

268 To assess the delivery experience, the Childbirth Experience and
269 Satisfaction Questionnaire (QESP) was chosen. This was built and validated in
270 Portuguese and has good internal consistency and a test-retest fidelity index [21].

271

272 **Plans to promote participant retention and complete follow-up {18b}**

273 Participants will be followed up during their usual hospitalization after
274 delivery that lasts 48 hours in this hospital.

275

276 **Data management {19}**

277 Following the institution's protocols, all data will be considered
278 anonymous, and participants will be identified by numbers. All source documents
279 will be stored in locked file cabinets with secure and limited access. The data will
280 be transferred to a secure online data cloud through double-checking between
281 researchers. Only the research group has an individual password to access the
282 data.

283

284 Confidentiality {27}

285 The study will be conducted in accordance with Brazilian rules and
286 regulations. All data generated in this study will remain confidential. Only the
287 research team has access to the study data. Access to data will only be provided
288 in the event of audits or regulatory regulation by the institution.

289

**290 Plans for collection, laboratory evaluation and storage of biological
291 specimens for genetic or molecular analysis in this trial/future use {33}**

292 Not applicable as no biological samples will be collected.

293

294 Statistical methods**295 Statistical methods for primary and secondary outcomes {20a}**

296 Obstetric, gynecological, sociodemographic data, among others, will be
297 compiled and collected using the statistical program Statistical Package for Social
298 Sciences (SPSS Statistics version 23) and tabulated in the Excel program. The
299 Shapiro-Wilk test will be applied to test the normality of the data, whether the data
300 follow a normal distribution or follow a non-normal distribution.

301 The data will be presented to the normality of these, according to the
302 quantitative variables that are normally distributed and continuously will be
303 presented as average (standard deviation). Continuous quantitative variables
304 without normal distribution will be presented in median (interquatile range).
305 Categorical variables will be assessed as frequencies and percentages.

306 For parametric data, comparison between the groups will be carried out

307 using the analysis of variance (ANOVA) test. Significance values lower than 0.05,
308 at the 95% confidence interval, will be interpreted as statistically significant. The
309 clinical relevance of recorded values will be confirmed through effect-size
310 calculations (Cohen d) based on significant differences. The following effects will
311 be taken into account: 0.00 to 0.49, low; 0.50 to 0.79, medium; and above 0.80,
312 high [33].

313

314 **Interim analyses {21b}**

315 No interim analysis will be performed.

316

317 **Methods for additional analyses (e.g., subgroup analyses) {20b}**

318 None planned.

319

320 **Methods in analysis to handle protocol non-adherence and any statistical** 321 **methods to handle missing data {20c}**

322 Any missing data and the reason for the missing data will be described for
323 each group. If necessary, a multiple imputation model will be applied.

324

325 **Plans to give access to the full protocol, participant level-data and** 326 **statistical code {31c}**

327 The datasets analyzed during the study will be available from the
328 corresponding author upon reasonable request.

329

330 **Oversight and monitoring**

331 **Composition of the coordinating center and trial steering committee {5d}**

332 The researchers involved in the study (see on title page) form the
333 coordinating center responsible for study coordination, monitoring, data
334 acquisition and management and statistical analysis.

335

336 **Composition of the data monitoring committee, its role and reporting
337 structure {21a}**

338 This study will not have a data monitoring committee, as it is a short-term
339 trial with minimal known risks.

340

341 **Adverse event reporting and harm {22}**

342 This study involves minimal known risks but the researcher responsible for
343 the evaluation will question the participants about possible adverse effects. Any
344 harm detected will be reported to the institution's research ethics committee.

345

346 **Frequency and plans for auditing trial conduct {23}**

347 No audits are planned because this trial is academic.

348

349 **Plans for communicating important protocol amendments to relevant
350 parties (e.g., trial participants, ethical committees) {25}**

351 According to national regulations, major modifications of the protocol
352 require a formal amendment to the protocol and are to be approved by the

353 institution's research ethics committee and modified in the Brazilian Registry of
354 Clinical Trials.

355

356 **Dissemination plans {31a}**

357 The trial results will be submitted for publication in relevant journals and
358 presented at conferences in the area of physiotherapy, gynecology and
359 obstetrics. In addition, the results will be published on the university's social
360 media using accessible language so that it is known to the population.

361

362 **Discussion**

363 The sensation of pain during labor is feared by pregnant women and may be one of the
364 factors that keep women away from the decision for vaginal delivery. Thus, health professionals
365 look for ways to relieve pain and improve the delivery experience of women. Non-pharmacological
366 methods of pain relief are widely used during childbirth because they have benefits without side
367 effects or contraindications [25].

368

369 Despite its widespread use, there is a lack of scientific evidence to support the use of
370 some techniques, including TENS. Thuvakaran et al [20], in a meta-analysis, observed that the
371 studies presented a difficulty in a detailed description with regard to randomization with the most
372 appropriate methods, as was done the allocation, masking and blinding of the study. Thus it was
373 detected that many studies had limitations that compromise the quality of the studies, therefore,
374 their conclusions.

375 With this research, it is expected to contribute to understanding the effects of the
376 intervention through TENS electrostimulation, in addition to other non-pharmacological pain relief
377 measures, in women in labor. Furthermore, with the dissemination of the conclusions obtained in
378 this study through publication in scientific journals and events in the area, health professionals
379 will have important information for conducting pain management through non-pharmacological
380 pain relief measures during the labor.

381

382 **Trial status**

383 The study was registered at the Brazilian Registry of Clinical Trials
384 (REBEC) (number RBR-68kh6j) on March 17, 2020. Recruitment for study began
385 in April 01,2020, and the planned recruitment completion date is February 28,
386 2022.

387

388 **Declarations**

389 **Acknowledgements**

390 Authors would like to thank Hospital Municipal Modesto de Carvalho
391 (HMMC) for providing the evaluation and treatment facilities used during the
392 present study. Besides, we would like to thank CAPES for financing the
393 development of the present study.

394

395 **Authors' contributions {31b}**

396 NTD and VSPB developed protocol concept and design. VSPB accounted
397 for volunteers' randomization and randomized allocation into the groups. NTD will
398 participate in the application of the protocol adopted for the project. PRS, TAC
399 review this manuscript elaborated by NTD.

400 NTD, PRS, TAC, VSPB, APMRB and CRCA will interpret the collected data.
401 RMCP still performed sample calculation. NTD elaborated the manuscript based
402 on the critical contributions by VCPB. All authors read and approved the final
403 manuscript. All named authors adhere to the authorship guidelines of Trials. All
404 authors have agreed to publication.

405

406 **Funding {4}**

407 The present study was financed in part by the Coordenação de Aperfeiçoamento de
408 Pessoal de Nível Superior (CAPES), Brazil – Finance Code 001. This financial source did not

409 This research project was developed by student Naiara Toledo Dias, under
410 the guidance of Professor Vanessa Santos Pereira Baldon in the Health Sciences
411 Post Graduation Program, at the Faculty of Medicine at the Federal University of
412 Uberlândia. The project was developed within the program that has financed by
413 the Coordination for the Improvement of Higher Education Personnel (CIHEP),
414 an institution that promotes the financing of postgraduate programs for masters
415 and doctorates in Brazil. There is no direct financing for project approval for its
416 realization, CAPES maintains only funding for graduate programs. Thus, the
417 financing of research-related expenses was the responsibility of the team of
418 researchers involved in the project.

419

420

421

422